Titre : Hypoglycémiants

Hypoglycémiants : Questions médicales fréquentes

Termes MeSH sélectionnés :

Programmed Cell Death 1 Receptor
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Hypoglycémiants : Questions médicales les plus fréquentes", "headline": "Hypoglycémiants : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Hypoglycémiants : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-16", "dateModified": "2025-03-11", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Hypoglycémiants" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Effets physiologiques des médicaments", "url": "https://questionsmedicales.fr/mesh/D045505", "about": { "@type": "MedicalCondition", "name": "Effets physiologiques des médicaments", "code": { "@type": "MedicalCode", "code": "D045505", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Inhibiteurs des glycoside hydrolases", "alternateName": "Glycoside Hydrolase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D065089", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs des glycoside hydrolases", "code": { "@type": "MedicalCode", "code": "D065089", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696.422.249" } } }, { "@type": "MedicalWebPage", "name": "Agonistes des récepteurs de l'amyline", "alternateName": "Amylin Receptor Agonists", "url": "https://questionsmedicales.fr/mesh/D065091", "about": { "@type": "MedicalCondition", "name": "Agonistes des récepteurs de l'amyline", "code": { "@type": "MedicalCode", "code": "D065091", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696.422.374" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de la dipeptidyl-peptidase IV", "alternateName": "Dipeptidyl-Peptidase IV Inhibitors", "url": "https://questionsmedicales.fr/mesh/D054873", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la dipeptidyl-peptidase IV", "code": { "@type": "MedicalCode", "code": "D054873", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696.422.500" } } }, { "@type": "MedicalWebPage", "name": "Secrétagogues à l'insuline", "alternateName": "Insulin Secretagogues", "url": "https://questionsmedicales.fr/mesh/D000092005", "about": { "@type": "MedicalCondition", "name": "Secrétagogues à l'insuline", "code": { "@type": "MedicalCode", "code": "D000092005", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696.422.625" } } }, { "@type": "MedicalWebPage", "name": "Agonistes du PPAR gamma", "alternateName": "PPAR-gamma Agonists", "url": "https://questionsmedicales.fr/mesh/D000092126", "about": { "@type": "MedicalCondition", "name": "Agonistes du PPAR gamma", "code": { "@type": "MedicalCode", "code": "D000092126", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696.422.688" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs du cotransporteur sodium-glucose de type 2", "alternateName": "Sodium-Glucose Transporter 2 Inhibitors", "url": "https://questionsmedicales.fr/mesh/D000077203", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs du cotransporteur sodium-glucose de type 2", "code": { "@type": "MedicalCode", "code": "D000077203", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696.422.750" } } } ], "about": { "@type": "MedicalCondition", "name": "Hypoglycémiants", "alternateName": "Hypoglycemic Agents", "code": { "@type": "MedicalCode", "code": "D007004", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Nunzio Cardullo", "url": "https://questionsmedicales.fr/author/Nunzio%20Cardullo", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Giuseppe Floresta", "url": "https://questionsmedicales.fr/author/Giuseppe%20Floresta", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Vera Muccilli", "url": "https://questionsmedicales.fr/author/Vera%20Muccilli", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Antonio Rescifina", "url": "https://questionsmedicales.fr/author/Antonio%20Rescifina", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Corrado Tringali", "url": "https://questionsmedicales.fr/author/Corrado%20Tringali", "affiliation": { "@type": "Organization", "name": "" } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Programmed cell death-1 blockade therapy in melanoma: Resistance mechanisms and combination strategies.", "datePublished": "2023-01-24", "url": "https://questionsmedicales.fr/article/36645031", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/exd.14750" } }, { "@type": "ScholarlyArticle", "name": "MicroRNAs Targeting Programmed Cell Death Protein 1 (PD-1) Promote Natural Killer Cell Exhaustion in Rheumatoid Arthritis.", "datePublished": "2022-12-24", "url": "https://questionsmedicales.fr/article/36640056", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.18502/ijaai.v21i6.11524" } }, { "@type": "ScholarlyArticle", "name": "Differential expression of programmed death 1 (PD-1) on various immune cells and its role in human leprosy.", "datePublished": "2023-04-21", "url": "https://questionsmedicales.fr/article/37153623", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2023.1138145" } }, { "@type": "ScholarlyArticle", "name": "A High Programmed Cell Death Protein 1 Hormone Receptor Score on Skin Biopsy is Associated with Sézary Syndrome Diagnosis: A Study of 91 Patients with Erythroderma.", "datePublished": "2022-09-06", "url": "https://questionsmedicales.fr/article/35758515", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2340/actadv.v102.1062" } }, { "@type": "ScholarlyArticle", "name": "Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.", "datePublished": "2022-11-25", "url": "https://questionsmedicales.fr/article/36442821", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.actbio.2022.11.043" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Actions chimiques et utilisations", "item": "https://questionsmedicales.fr/mesh/D020164" }, { "@type": "ListItem", "position": 3, "name": "Actions pharmacologiques", "item": "https://questionsmedicales.fr/mesh/D020228" }, { "@type": "ListItem", "position": 4, "name": "Effets physiologiques des médicaments", "item": "https://questionsmedicales.fr/mesh/D045505" }, { "@type": "ListItem", "position": 5, "name": "Hypoglycémiants", "item": "https://questionsmedicales.fr/mesh/D007004" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Hypoglycémiants - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Hypoglycémiants", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-04", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Hypoglycémiants", "description": "Comment diagnostiquer une hypoglycémie ?\nQuels tests sont utilisés pour le diabète ?\nQuels symptômes indiquent une hypoglycémie ?\nQuand consulter un médecin pour hypoglycémie ?\nQuel rôle joue l'HbA1c dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D007004?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Hypoglycémiants", "description": "Quels sont les signes d'une hypoglycémie ?\nComment reconnaître une hypoglycémie sévère ?\nLes symptômes varient-ils selon les personnes ?\nQuels symptômes nécessitent une intervention rapide ?\nLes symptômes peuvent-ils être confondus avec d'autres ?", "url": "https://questionsmedicales.fr/mesh/D007004?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Hypoglycémiants", "description": "Comment prévenir l'hypoglycémie ?\nQuel rôle joue l'exercice dans la prévention ?\nLes patients doivent-ils surveiller leur glycémie ?\nComment éduquer les patients sur l'hypoglycémie ?\nLes régimes alimentaires peuvent-ils aider ?", "url": "https://questionsmedicales.fr/mesh/D007004?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Hypoglycémiants", "description": "Quels sont les principaux hypoglycémiants ?\nComment administrer du glucose en cas d'hypoglycémie ?\nQuels sont les effets secondaires des hypoglycémiants ?\nComment ajuster le traitement hypoglycémiant ?\nLes hypoglycémiants sont-ils efficaces pour tous ?", "url": "https://questionsmedicales.fr/mesh/D007004?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Hypoglycémiants", "description": "Quelles sont les complications de l'hypoglycémie ?\nL'hypoglycémie peut-elle entraîner des séquelles ?\nComment l'hypoglycémie affecte-t-elle la qualité de vie ?\nLes complications sont-elles réversibles ?\nQuels sont les risques à long terme de l'hypoglycémie ?", "url": "https://questionsmedicales.fr/mesh/D007004?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Hypoglycémiants", "description": "Quels sont les facteurs de risque d'hypoglycémie ?\nL'âge influence-t-il le risque d'hypoglycémie ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe stress peut-il aggraver l'hypoglycémie ?\nLes médicaments peuvent-ils influencer le risque ?", "url": "https://questionsmedicales.fr/mesh/D007004?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une hypoglycémie ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'hypoglycémie est diagnostiquée par des tests de glycémie inférieure à 70 mg/dL." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diabète ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent la glycémie à jeun, l'HbA1c et le test de tolérance au glucose." } }, { "@type": "Question", "name": "Quels symptômes indiquent une hypoglycémie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent tremblements, sueurs, confusion et palpitations." } }, { "@type": "Question", "name": "Quand consulter un médecin pour hypoglycémie ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Consultez un médecin si les symptômes persistent ou s'aggravent." } }, { "@type": "Question", "name": "Quel rôle joue l'HbA1c dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'HbA1c évalue le contrôle glycémique sur 2-3 mois, utile pour le diagnostic du diabète." } }, { "@type": "Question", "name": "Quels sont les signes d'une hypoglycémie ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent fatigue, irritabilité, faim intense et vertiges." } }, { "@type": "Question", "name": "Comment reconnaître une hypoglycémie sévère ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Une hypoglycémie sévère peut provoquer des convulsions, une perte de conscience ou un coma." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon les personnes ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier d'une personne à l'autre en fonction de la sensibilité." } }, { "@type": "Question", "name": "Quels symptômes nécessitent une intervention rapide ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes graves comme confusion, convulsions ou perte de conscience nécessitent une aide immédiate." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils être confondus avec d'autres ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent être confondus avec ceux d'autres conditions comme l'anxiété ou l'AVC." } }, { "@type": "Question", "name": "Comment prévenir l'hypoglycémie ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Prévenir l'hypoglycémie nécessite une alimentation équilibrée et un suivi régulier de la glycémie." } }, { "@type": "Question", "name": "Quel rôle joue l'exercice dans la prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "L'exercice régulier aide à réguler la glycémie et à prévenir les épisodes d'hypoglycémie." } }, { "@type": "Question", "name": "Les patients doivent-ils surveiller leur glycémie ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la surveillance régulière de la glycémie est essentielle pour prévenir l'hypoglycémie." } }, { "@type": "Question", "name": "Comment éduquer les patients sur l'hypoglycémie ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "L'éducation doit inclure la reconnaissance des symptômes et les mesures à prendre en cas d'hypoglycémie." } }, { "@type": "Question", "name": "Les régimes alimentaires peuvent-ils aider ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un régime alimentaire équilibré et riche en fibres peut aider à stabiliser la glycémie." } }, { "@type": "Question", "name": "Quels sont les principaux hypoglycémiants ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les principaux hypoglycémiants incluent la metformine, les sulfonylurées et les inhibiteurs DPP-4." } }, { "@type": "Question", "name": "Comment administrer du glucose en cas d'hypoglycémie ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Le glucose peut être administré par voie orale ou intraveineuse selon la gravité." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des hypoglycémiants ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure des nausées, des diarrhées et des hypoglycémies." } }, { "@type": "Question", "name": "Comment ajuster le traitement hypoglycémiant ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement doit être ajusté en fonction des niveaux de glycémie et des symptômes." } }, { "@type": "Question", "name": "Les hypoglycémiants sont-ils efficaces pour tous ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Non, leur efficacité peut varier selon le type de diabète et la réponse individuelle." } }, { "@type": "Question", "name": "Quelles sont les complications de l'hypoglycémie ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des troubles neurologiques, des accidents vasculaires cérébraux et des chutes." } }, { "@type": "Question", "name": "L'hypoglycémie peut-elle entraîner des séquelles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des épisodes répétés peuvent causer des dommages neurologiques permanents." } }, { "@type": "Question", "name": "Comment l'hypoglycémie affecte-t-elle la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "L'hypoglycémie fréquente peut entraîner une anxiété accrue et une diminution de la qualité de vie." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles si l'hypoglycémie est traitée rapidement." } }, { "@type": "Question", "name": "Quels sont les risques à long terme de l'hypoglycémie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les risques à long terme incluent des troubles cognitifs et une augmentation du risque cardiovasculaire." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque d'hypoglycémie ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent un traitement intensif du diabète, une alimentation irrégulière et l'alcool." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'hypoglycémie ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées sont plus susceptibles de souffrir d'hypoglycémie en raison de la sensibilité accrue." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de diabète peuvent augmenter le risque d'hypoglycémie." } }, { "@type": "Question", "name": "Le stress peut-il aggraver l'hypoglycémie ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut affecter la glycémie et augmenter le risque d'hypoglycémie." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils influencer le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments, comme les bêta-bloquants, peuvent masquer les symptômes d'hypoglycémie." } } ] } ] }

Sources (10000 au total)

Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.

Immune checkpoint blockade therapy targeting programmed death-1 (PD-1) or its major ligand programmed death-ligand 1 (PD-L1) has achieved remarkable success in the treatment of several tumors, includi...

Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.

Pembrolizumab or nivolumab plus chemotherapy was approved as a first-line treatment for high programmed cell death ligand 1 (PD-L1)-expressing esophageal squamous cell carcinoma (ESCC) by the European... Post hoc analysis of the Chinese JUPITER-06 study focusing on efficacy stratified by PD-L1 tumor proportion score (TPS; using JS311 antibody) was conducted. Electronic databases were searched to ident... The post hoc analysis of JUPITER-06 showed more prominent clinical benefit with PD-1 antibody plus chemotherapy than with chemotherapy alone in both the high and low PD-L1-expressing subgroups. Five r... This study provided novel evidence supporting the superiority of PD-1 antibody plus chemotherapy to chemotherapy alone in patients with advanced ESCC with low PD-L1 expression. Further studies of pred...

Association between programmed death-1 pathway and major depression.

Major depression (MD) may be associated with inflammation and immunity. PD-1 (programmed death-1), PD-L1 (programmed death-ligand 1) and PD-L2 (programmed death-ligand 2) are among the inhibitory immu... During a period of 2 years, patients with MD and healthy controls were recruited from a medical centre in this study. The diagnosis of MD was established according to the DSM-5 criteria. The severity ... A total of 54 patients with MD and 38 healthy controls were recruited. According to the analyses, there is a significantly higher PD-L2 level in MD than in healthy controls and lower PD-1 level after ... It was found that PD-1 pathway might play an important role in MD. We need a large sample to prove these results in the future....

Programmed cell death protein 1 is a marker for neoadjuvant chemotherapy response in triple-negative breast cancer.

Tumor-infiltrating lymphocytes are detectable in up to 75% of triple-negative breast cancer. The composition of these infiltrates may influence prognosis and is not known regarding regulatory or effec... This was a retrospective observational study. Clinical and pathological data from 38 triple-negative breast cancer patients treated with neoadjuvant chemotherapy at the University Hospital (HUCFF/UFRJ... Statistically significant changes in stromal tumor-infiltrating lymphocyte categories were observed before and post-neoadjuvant chemotherapy, with 32% of intermediate cases becoming high. The correlat... In this study, we observed that chemotherapy significantly increases stromal tumor-infiltrating lymphocytes, CD8 T cells, as well as CD8/FoxP3 ratio. Most importantly, programmed cell death protein 1 ...